Clinical trials

Clinical trials web imageThe Dementia Centre has become recognised as a leading research centre for aged care, both nationally and internationally. Conducting clinical trials of new dementia treatments demonstrates our diversification into neuroscience research and provides important hope for people living with dementia.

MISSIONAD


Sponsor: Eisai Pharmaceuticals
Name: A placebo-controlled, double-blind, parallel-group, 24-month study to evaluate the efficacy and safety of E2609 in subjects with early Alzheimers disease
Drug: Elenbecestat
Type of effect: Disease-modifying therapy

COG0102


Sponsor: Cognitive Therapeutics
Name: A randomised, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of three doses of CT1812 in subjects with mild to moderate Alzheimer’s disease
Drug: CT1812
Type of effect: Disease-modifying therapy

GN39763


Sponsor: Genetech
Name: A phase II, multicenter, randomised, double-blind, placebo-controlled, parallel-group, efficacy, and safety study of  MTAU9937A in patients with prodromal to mild Alzheimer's disease
Drug: MTAU9937A
Type of effect: Disease-modifying therapy 

Contact
  • If you would like more information regarding these trials please contact a trial coordinator on +61 9 9597 6515 or +61 3 9597 6516 or This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Download the Aged Psychiatry Clinical Trials Flyer